Currently, there are 361.49M common shares owned by the public and among those 349.07M shares have been available to trade.
The company’s stock has a 5-day price change of -33.70% and -28.02% over the past three months. LXRX shares are trading -20.26% year to date (YTD), with the 12-month market performance down to -1.61% lower. It has a 12-month low price of $0.92 and touched a high of $3.73 over the same period. LXRX has an average intraday trading volume of 2.80 million shares. The stock is trading above its simple moving averages at the SMA20, SMA50, and SMA200, as the current price level is off by -32.48%, -28.92%, and -36.27% respectively.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Institutional ownership of Lexicon Pharmaceuticals Inc (NASDAQ: LXRX) shares accounts for 76.93% of the company’s 361.49M shares outstanding.
It has a market capitalization of $275.92M and a beta (3y monthly) value of 1.24. The earnings-per-share (ttm) stands at -$0.77. Price movements for the stock have been influenced by the stock’s volatility, which stands at 10.69% over the week and 7.37% over the month.
Earnings per share for the fiscal year are expected to increase by 14.05%, and 12.42% over the next financial year.
Looking at the support for the LXRX, a number of firms have released research notes about the stock. H.C. Wainwright stated their Buy rating for the stock in a research note on June 17, 2024, with the firm’s price target at $10. Leerink Partners coverage for the Lexicon Pharmaceuticals Inc (LXRX) stock in a research note released on April 30, 2024 offered a Outperform rating with a price target of $5. Jefferies was of a view on March 07, 2023 that the stock is Hold, while Piper Sandler gave the stock Overweight rating on August 12, 2022, issuing a price target of $10. JP Morgan on their part issued Neutral rating on January 29, 2021.
